Digital Content 
NEWS #PharmaBuzz
05 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/05/3037413/12401/en/Tenax-Therapeutics-Expands-Phase-3-LEVEL-Program-Advancing-Two-TNX-103-Oral-Levosimendan-Registrational-Studies-for-the-Treatment-of-PH-HFpEF.html
13 Aug 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/08/13/2929628/0/en/Tenax-Therapeutics-Reports-Second-Quarter-2024-Financial-Results-and-Provides-a-Corporate-Update.html
30 Apr 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/04/30/2872119/0/en/Tenax-Therapeutics-Announces-New-U-S-Patent-Covering-the-Use-of-Levosimendan-in-Pulmonary-Hypertension-with-Heart-Failure-with-Preserved-Ejection-Fraction-PH-HFpEF.html
09 Apr 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/04/09/2859987/0/en/Tenax-Therapeutics-to-Host-KOL-Event-LEVEL-Setting-the-Scientific-Rationale-for-Levosimendan-as-a-Potential-First-Treatment-for-PH-HFpEF-and-the-Ongoing-Phase-3-LEVEL-Study.html
28 Mar 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/03/28/2854007/0/en/Tenax-Therapeutics-Provides-Business-and-Clinical-Development-Updates-with-Full-Year-2023-Financial-Results.html
29 Feb 2024
// PRESS RELEASE
https://feeds.issuerdirect.com/news-release.html?newsid=6432598367320275
Share 